利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

71 条记录 (耗时 0.017 秒)

    Method for making N-(fluorosulfonyl) dimethylamine
    1.
    发明授权
    Method for making N-(fluorosulfonyl) dimethylamine 有权

    公开(公告)号：US10106495B2

    公开(公告)日：2018-10-23

    申请号：US15816719

    申请日：2017-11-17

    申请人： Trinapco, Inc.

    发明人： Martin Reid Johnson

    IPC分类号： C07C303/34

    摘要： Dimethylamine (Me2NH) is reacted with sulfuryl fluoride (SO2F2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FSO2NMe2), tetramethylsulfamide (SO2(NMe2)2), or a combination thereof. A second phase, which may include dimethylamine hydrofluoride (Me2NH2F), may be also formed and separated from the first phase. FSO2NMe2 or SO2(NMe2)2 is then isolated from the first phase. For example, the first phase may be a liquid phase, and FSO2NMe2 and SO2(NMe2)2 are separated by distillation, optionally under reduced pressure.

    METHOD FOR MAKING N-(FLUOROSULFONYL) DIMETHYLAMINE
    2.
    发明申请
    METHOD FOR MAKING N-(FLUOROSULFONYL) DIMETHYLAMINE 审中-公开

    公开(公告)号：US20180141900A1

    公开(公告)日：2018-05-24

    申请号：US15816719

    申请日：2017-11-17

    申请人： Trinapco, Inc.

    发明人： Martin Reid Johnson

    IPC分类号： C07C303/34

    CPC分类号： C07C303/34 ,  C07C307/06 ,  C07C307/02

    摘要： Dimethylamine (Me2NH) is reacted with sulfuryl fluoride (SO2F2) to form at least a first phase comprising N-(fluoro sulfonyl) dimethylamine (FSO2NMe2), tetramethylsulfamide (SO2(NMe2)2), or a combination thereof. A second phase, which may include dimethylamine hydrofluoride (Me2NH2F), may be also formed and separated from the first phase. FSO2NMe2 or SO2(NMe2)2 is then isolated from the first phase. For example, the first phase may be a liquid phase, and FSO2NMe2 and SO2(NMe2)2 are separated by distillation, optionally under reduced pressure.

    Ethanolamine derivatives
    7.
    发明授权
    Ethanolamine derivatives 失效

    公开(公告)号：US4990664A

    公开(公告)日：1991-02-05

    申请号：US230357

    申请日：1988-08-10

    申请人： Ian F. Skidmore ,  Alan Naylor ,  Harry Finch ,  Lawrence H. C. Lunts ,  Ian B. Campbell ,  Peter C. North

    发明人： Ian F. Skidmore ,  Alan Naylor ,  Harry Finch ,  Lawrence H. C. Lunts ,  Ian B. Campbell ,  Peter C. North

    IPC分类号： C07D295/18 ,  A61K31/135 ,  A61K31/165 ,  A61K31/18 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/47 ,  A61P5/38 ,  C07C67/00 ,  C07C231/00 ,  C07C237/30 ,  C07C301/00 ,  C07C303/34 ,  C07C309/66 ,  C07C313/00 ,  C07C323/25 ,  C07C323/27 ,  C07C323/41 ,  C07C323/42 ,  C07C323/43 ,  C07C323/44 ,  C07C323/49 ,  C07C323/60 ,  C07C323/62 ,  C07C323/65 ,  C07C325/00 ,  C07D213/32 ,  C07D213/65 ,  C07D215/26

    CPC分类号： C07C323/62 ,  C07C323/25 ,  C07D213/32

    摘要： The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and solvates thereof, wherein Z represents the group ##STR2## where A represents a group selected from HOR.sup.3 --, R.sup.6 NH(CH.sub.2)p--, R.sup.10 R.sup.11 N--, R.sup.12 OCH.sub.2 --, CH.sub.3 SO.sub.2 CH.sub.2 -- or NCCH.sub.2 --;where R.sup.3 is a C.sub.1-3 alkylene group,R.sup.6 is a group selected from R.sup.7 CO--, R.sup.7 NHCO--, R.sup.7 R.sup.8 NSO.sub.2 -- orR.sup.9 SO.sub.2 --, and p is zero or 1,R.sup.7 and R.sup.8 each represent a hydrogen atom or a C.sub.1-3 alkyl group,R.sup.9 is a C.sub.1-3 alkyl group,R.sup.10 and R.sup.11 each represent a hydrogen atom or a C.sub.1-4 alkyl group or, when R.sup.10 is a hydrogen atom, R.sup.11 may also be a C.sub.1-4 alkoxycarbonyl group, andR.sup.12 is a C.sub.1-3 alkyl group; ##STR3## where one of R.sup.4 and R.sup.5 is a hydroxy group and the other is a hydrogen or halogen atom or a hydroxy group; ##STR4## where A.sup.1 is either a chlorine atom or a --CF.sub.3 group; ##STR5## X represents a bond or a C.sub.1-7 alkenylene or C.sub.2-7 alkynylene chain, andY represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain, with the proviso that the sum total of carbon atoms in X and Y is 2 to 10;R represents a hydrogen atom or a C.sub.1-3 alkyl group;R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-3 alkyl group; with the proviso that the sum total of carbon atoms inR.sup.1 and R.sup.2 is not more than 4;Q represents a pyridyl group optionally substituted by one or two substituents selected from halogen atoms or hydroxy, C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups, or Q represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups C.sub.1-6 alkyl, nitro, --(CH.sub.2).sub.q R.sup.13 or --O(CH.sub.2).sub.r R.sup.14, or Q represents a phenyl group substituted by an alkylenedioxy group of formula --O(CH.sub.2).sub.t O--; whereR.sup.13 represents hydroxy, C.sub.1-6 alkoxy, cyano, --NR.sup.15 R.sup.16, --NR.sup.17 COR.sup.18, --NR.sup.17 SO.sub.2 R.sup.19, --COR.sup.20, --SR.sup.21, --SOR.sup.22 or --SO.sub.2 R.sup.22 ;R.sup.14 represents hydroxy or C.sub.1-4 alkoxy;R.sup.15 and R.sup.16 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.15 R.sup.16 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--;R.sup.17 represents a hydrogen atom or a C.sub.1-4 alkyl group;R.sup.18 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or --NR.sup.15 R.sup.16 group;R.sup.19 represents C.sub.1-4 alkyl, phenyl or --NR.sup.15 R.sup.16 ;R.sup.20 represents hydroxy, C.sub.1-4 alkoxy or --NR.sup.15 R.sup.16 ;R.sup.21 represents a hydrogen atom or a C.sub.1-4 alkyl or phenyl group;R.sup.22 represents a C.sub.1-4 alkyl or phenyl group;q represents an integer from 0 to 3;r represents 2 or 3; andt represents 1 or 2.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.